Amarin Corporation PLC (AMRN)
Amarin Corporation plc is a Dublin-based pharmaceutical company whose business centers on the development and commercialization of therapies for cardiovascular disease. The listed security is a depositary receipt representing common stock on NASDAQ under the symbol AMRN. The company’s commercial product is VASCEPA, a prescription omega-3 fatty acid treatment used alongside diet to help reduce triglyceride levels in adults with severe hypertriglyceridemia. Amarin distributes its products primarily through wholesalers, selected regional wholesalers, and retail and mail-order pharmacy channels. It also maintains a collaboration with Mochida Pharmaceutical Co., Ltd. focused on drug products and indications based on the active pharmaceutical ingredient in Vascepa, EPA. Formerly known as Ethical Holdings plc, the company adopted the Amarin name in 1999 and was incorporated in 1989.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AMRN
|
$14.89
|
8.3% Upside
|
Fair
|
$12.50
|
-9.1% Downside
|
Fair
|
Fair
|
0.0%
|
October 28, 2026
|
0.7x
|
1.6x
|
290.4 M
|
-17.035 M
|
2.5%
|
91.9%
|
1.1
|
-57.4%
|
